Printer Friendly

Articles from M2 Pharma (June 21, 2019)

1-14 out of 14 article(s)
Title Author Type Words
ANI Pharmaceuticals gains FDA approval for Vancomycin Hydrochloride for Oral Solution. 179
ArQule Presents Preliminary Results from Its Phase 1/2 Study of Miransertib in Patients with PIK3CA-related Overgrowth Spectrum and Proteus syndrome in an Oral Presentation at the European Society of Human Genetics Conference. Conference news 425
Camurus gets FDA green light to launch phase 3 trial with CAM2029 for treatment of acromegaly. 204
Edesa Biotech to launch its US clinical study of EB01 following FDA approval. 265
FDA Approves US Merck's Keytruda as Monotherapy for Patients with Metastatic Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy. 678
First Patient Dosed in a Phase 1 Trial of SIRPI[+ or -] Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors. 209
Imara Presents Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease. 965
Lynparza Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer. 163
Novo Nordisk receives EU marketing authorisation for Esperoct. 194
Onxeo commences proof-of-concept preclinical phase for optimised lead candidate OX401. 216
Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome. 474
Spectrum Plastics Group closes Earnan Biomedical acquisition. 202
Triumvira Immunologics IND and CTA Cleared by US FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19. 394
Versiti Blood Research receives USD13m NIH research grant. 189

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters